Needham & Company Maintained Buy on Medgenics (MDGN) Following Announced Development Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Medgenics Obtains Rights to First-in-Class Biologic for Severe Pediatric Onset IBD
June 6, 2016 7:00 AM EDTPHILADELPHIA, PA -- (Marketwired) -- 06/06/16 -- (NYSE MKT: MDGN)
Collaboration with Kyowa Hakko Kirin to develop anti-LIGHT monoclonal antibody Second program from research collaboration with The Children's Hospital of Philadelphia (CHOP) Center for Applied Genomics (CAG) Data from signal finding study in Severe Pediatric Onset Inflammatory Bowel Disease patients expected in first half 2017Medgenics, Inc. (NYSE MKT: MDGN) today announced that it has entered into a collaboration with... More
